Apr 04, 2013
Tokai Pharmaceuticals Announces Presentation of Galeterone Mechanism of Action Data at AACR Annual Meeting 2013
CAMBRIDGE, MASS., April 4, 2013—Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company will present preclinical data highlighting the CYP17 lyase inhibition profile of galeterone in prostate cancer models at the American Association for Cancer Research (AACR) Annual Meeting 2013 in Washington, D.C. These data will be presented by Douglas B. Jacoby, Ph.D., head of preclinical research, Tokai Pharmaceuticals, on Sunday, April 7, 2013 from 1 p.m. to 5 p.m. ET in a poster presentation titled, “Differential Inhibitory Effects of Galeterone, Abiraterone, Orteronel and Ketoconazole on CYP17A1 and Steroidogenesis,” abstract number 83.
About Galeterone (TOK-001)
Galeterone is a proprietary small molecule, oral drug for the treatment of prostate cancer that disrupts androgen receptor signaling via a novel triple mechanism of action. In preclinical studies, galeterone acted as a highly selective CYP17 lyase inhibitor, as a potent androgen receptor antagonist, and decreased androgen receptor levels in prostate tumors – the only drug in development that has been shown to exhibit all three of these properties. Galeterone combines these three distinct mechanisms of action in one therapeutic compound. Results from the ARMOR1 Phase 1 clinical trial showed that galeterone demonstrated clinical activity and was well tolerated in patients with castration-resistant prostate cancer (CRPC). Galeterone is currently being evaluated in a Phase 2 study, ARMOR2, in patients with CRPC as part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, galeterone (TOK- 001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined to disrupt androgen receptor signaling in one oncotherapeutic. Galeterone is currently being evaluated in a Phase 2 study, ARMOR2, in patients with castration-resistant prostate cancer (CRPC).Based in Cambridge, Massachusetts, Tokai is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visitwww.tokaipharma.com.
Pure Communications, Inc.
(910) 232-7166All news about Tokai Pharmaceuticals